Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 6, 2008, Pages 1436-1439

  Scholl, Peter F ^a   Groopman, John D ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALBUMIN; LYSINE;

ARTICLE; BLOOD SAMPLING; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; ISOTOPE DILUTION ASSAY; LIVER CANCER; LONG TERM EXPOSURE; MASS SPECTROMETRY; PRIORITY JOURNAL; STORAGE;

AFLATOXIN B1; AFLATOXINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; LYSINE; MALE; MASS SPECTROMETRY; SERUM ALBUMIN;

EID: 53349152027     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2926     Document Type: Article

References (20)

1. Kensler TW, Qian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver. Nat Rev Cancer 2003;3:321-9.
2. Raney VM, Harris TM, Stone MP. DNA conformation mediates aflatoxin B1-DNA binding and the formation of guanine N7 adducts by aflatoxin B1 8,9-exo-epoxide. Chem Res Toxicol 1993;6:64-8.
3. Essigmann JM, Croy RG, Nadzan AM, et al. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A 1977;74:1870-4.
4. Sabbioni G. Chemical and physical properties of the major serum albumin adduct of aflatoxin B1 and their implications for the quantification in biological samples. Chem Biol Interact 1990;75:1-15.
5. Guengerich FP, Arneson KO, Williams KM, Deng Z, Harris TM. Reaction of aflatoxin B1 oxidation products with lysine. Chem Res Toxicol 2002;15:780-92.
6. Wild CP, Hasegawa R, Barraud L, et al. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol Biomarkers Prev 1996;5:179-89.
7. Wild CP, Garner RC, Montesano R, Tursi F. Aflatoxin B 1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 1986;7:853-8.
8. Sabbioni G, Skipper PL, Büchi G, Tannenbaum SR. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 1987;8:819-24.
9. Wild CP, Jiang YZ, Sabbioni G, Chapot B, Montesano R. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res 1990;50:245-51.
10. Gan LS, Skipper PL, Peng XC, et al. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis 1988;9:1323-5.
11. Sabbioni G, Ambs S, Wogan GN, Groopman JD. The aflatoxin-lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples. Carcinogenesis 1990;11:2063-6.
12. Scholl PF, Turner PC, Sutcliffe AE, et al. Quantitative comparison of aflatoxin B1 serum albumin adducts in humans by isotope dilution mass spectrometry and ELISA. Cancer Epidemiol Biomarkers Prev 2006;15:823-6.
13. Scholl PF, McCoy L, Kensler TW, Groopman JD. Quantitative analysis and chronic dosimetry of the aflatoxin B1 plasma albumin adduct Lys-AFB1 in rats by isotope dilution mass spectrometry. Chem Res Toxicol 2006;19:44-9.
14. Scholl PF, Groopman JD. Synthesis of 5,5,6,6-D4-L-lysine- aflatoxin B1 for use as a mass spectrometric internal standard. J Labelled Comp Radiopharm 2005;47:807-15.
15. McCoy LF, Scholl PF, Schleicher RL, Groopman JD, Powers CD, Pfeiffer CM. Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2203-10.
16. Scholl PF, Mcoy L, Kensler TW, Groopman JD. Development of a quantitative LCMS method for the analysis of aflatoxin B1 serum albumin adducts. Abstr Pap Am Chem Soc 2004;228:U379-9.
17. Kensler TW, Egner PA, Wang JB, et al. Strategies for chemoprevention of liver cancer. Eur J Cancer Prev 2002;11:S58-64.
18. Wild CP, Hudson GJ, Sabbioni G, et al. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992;1:229-34.
19. Turner PC, Collinson AC, Cheung YB, et al. Aflatoxin exposure in utero causes growth faltering in Gambian infants. Int J Epidemiol 2007;36:1119-25.
20. Strosnider H, Azziz-Baumgartner E, Banziger M, et al. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect 2006;114:1898-903.